Energy XXI (Bermuda) Limited (NASDAQ:EXXI), an oil and gas exploration and production company, has appointed Bruce W. Busmire Chief Financial Officer, replacing West Griffin who is stepping down effective today. Busmire will lead Energy XXI's corporate finance, accounting, information technology, investor relations, planning and strategy functions.He has more than 34 years of experience in the oil and gas industry and financial markets and was most recently Chief Financial Officer of Venari Resources, a private equity backed Deepwater Gulf of Mexico exploration company. Prior to that, he was in key financial executive positions with Anadarko Petroleum Corporation for eight years.Energy XXI (Bermuda) Limited (NASDAQ:EXXI) also provided a business update, reporting a return of oil volumes impacted during fiscal Q1 due to downtime experienced on two separate third-party pipeline operations. A pipeline at the Main Pass 311 field is back online delivering 950 net barrels of oil equivalent per day (BOE/d) and the Williams natural gas pipeline at the Ship Shoal field (100% WI / 87.5% NRI), is back online adding an additional 3,100 net BOE/d.Ohr Pharmaceuticals Inc (NASDAQ:OHRP), an ophthalmology research and development company, reported additional positive clinical data from the IMPACT study were presented at the 2014 American Academy of Ophthalmology Annual Scientific Meeting, in Chicago, Illinois. The IMPACT study is a nine month phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration. The data, presented in the AAO late breaker session by Dr. David S. Boyer on Saturday, October 18, demonstrated that the combination of OHR-102 plus Lucentis resulted in a marked improvement in subretinal hyperreflective material, an anatomical biomarker for wet-AMD.The regression of SHRM observed was greater in the OHR-102 combination arm compared to the Lucentis monotherapy arm. A clear relationship was demonstrated between this reduction in the SHRM biomarker and the improvements in visual acuity seen in the study. In addition, the IMPACT study demonstrated that the OHR-102 combination arm had a greater proportion of patients with total resolution of SHRM compared to the Lucentis monotherapy arm. Ohr Pharmaceuticals Inc (NASDAQ:OHRP) trades in a 52-week range of $6.01 to $20.00.Cubist Pharmaceuticals Inc (NASDAQ:CBST) said its president and chief operating officer Robert J. Perez will take over as Chief Executive Officer, effective January 1, 2015, replacing Michael Bonney who is retiring. Bonney will become non-executive Chair of Cubist's Board of Directors. Current Board Chair, Kenneth M. Bate, will become Lead Independent Director. Perez has served in various senior positions at Cubist for 11 years. He was appointed COO in 2007, President in 2012 and has been a member of the Board since April 2014. Cubist Pharmaceuticals Inc (NASDAQ:CBST) are trading at $66.52 with a 52-week range of $58.50 - $82.12.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
